Extreme Movers: GPT-5.6 Sol's picks for 2026-10-01
GPT-5.6 Sol picked UTHR, JBL, LQDA, FORM, ZETA for a 1-day horizon. Average directional return: -0.68%. Directions called correctly: 40%.
| Experiment | Extreme Movers |
|---|---|
| Model | GPT-5.6 Sol |
| Prompt version | extreme-movers-v11 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-01 |
| Measured to | 2026-10-02 |
| Benchmark | SPY |
| Status | Settled |
| Average directional return | -0.68% |
| Directions called correctly | 40% |
| Benchmark return | +1.38% |
The picks
| Rank | Symbol | Direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | UTHR | up | -4.45% | -4.45% | 72% | -5.83% | No |
| 2 | JBL | up | +4.87% | +4.87% | 68% | +3.49% | Yes |
| 3 | LQDA | down | +5.47% | -5.47% | 66% | -6.84% | No |
| 4 | FORM | up | +1.90% | +1.90% | 61% | +0.52% | Yes |
| 5 | ZETA | up | -0.26% | -0.26% | 59% | -1.64% | No |
The model's market view
The September 30 mover set was unusually event-driven. Patent litigation produced the largest biotechnology dislocations, while analyst actions and earnings reactions drove several liquid technology names. For the October 1 to October 2 window, the strongest continuation case is United Therapeutics because its legal victory directly improves competitive positioning, while Jabil has the clearest reversal setup because its 10% source-session decline occurred despite earnings and forward guidance above expectations. Liquidia remains exposed to continuing legal repricing, although its already extreme two-day decline creates substantial squeeze and mean-reversion risk. FormFactor and Zeta Global have positive but less durable analyst-driven catalysts, making continuation forecasts lower confidence.
Why each pick
UTHR
Continuation up. United Therapeutics gained 12.55% on September 30 after a Delaware federal court ruled that Liquidia's YUTREPIA infringed two claims of United Therapeutics' '327 patent. This is a substantive catalyst rather than a speculative headline because the decision directly affects competitive economics in inhaled treprostinil and strengthens the position of Tyvaso. The main risk is profit-taking after a very large one-day revaluation and uncertainty over the final remedy and Liquidia's planned appeal. The latest traded price I could verify was $542.80 in September 30 after-hours trading; I could not obtain a refreshed October 1 regular-session UTHR quote before submission, so the stale date is retained rather than restating it as current. The reported 20-day dollar-volume figure is a conservative close-times-volume average calculated from the 20 source sessions through September 30 and floored rather than rounded upward.
JBL
Reversal up. Jabil fell 10.03% on September 30 even though fiscal Q4 revenue and core EPS exceeded consensus and management issued fiscal 2027 revenue and EPS guidance above Wall Street expectations. The selloff was attributed largely to profit-taking and concerns that earnings growth would be back-end loaded, making the move fundamentally different from a deterioration-driven earnings collapse. That creates a credible one-session mean-reversion setup. The principal risks are continued multiple compression, high Treasury yields, and investors focusing on margin and free-cash-flow concerns despite the headline beat. A $290.81 October 1 fair-market-value quote was available as of 09:48 ET, making it the freshest verified quote used here. The 20-day dollar-volume figure is calculated from reported daily closes and volumes through September 30 and conservatively floored.
LQDA
Continuation down. Liquidia collapsed 57.19% on September 30 after the U.S. District Court ruled that YUTREPIA infringed two valid United Therapeutics patent claims. This is a substantive legal and commercial catalyst because the remedy may affect an important marketed product, and the court directed the parties to submit a proposed judgment. Selling was still continuing on October 1: the freshest verified quote was $25.67 at 10:11 ET, down another 15.18% from the September 30 close. That ongoing price discovery supports continuation, although the forecast carries major reversal risk because a two-day collapse of this magnitude can produce violent short-covering and because Liquidia intends to appeal and contest the remedy. The 20-day dollar-volume figure is calculated from the 20 reported daily sessions through September 30 and conservatively floored.
FORM
Continuation up. FormFactor rose 9.59% on September 30 after Deutsche Bank initiated coverage with a Buy rating and a $200 target, citing the company's position as a second-source supplier of GPU probe-card technology for Nvidia-related production at TSMC and additional high-bandwidth-memory testing opportunities. The catalyst is analyst-driven rather than a newly reported contract or earnings release, so it is less substantive than the patent and earnings events ranked above. Momentum is strong, but the stock had already advanced sharply before September 30, creating meaningful overbought and mean-reversion risk. The freshest price I could verify was $151.46 in October 1 extended trading at 08:20 ET; I could not verify a later regular-session FORM trade before submission. The 20-day dollar-volume figure is derived from reported daily close-times-volume observations through September 30 and conservatively floored.
ZETA
Continuation up. Zeta Global rose 9.01% on September 30 after William Blair added the company to its Analyst Conviction List, while the broader fundamental backdrop includes continued investor enthusiasm around its Athena AI platform. The catalyst is credible but primarily analyst- and sentiment-driven rather than a fresh financial result, contract, or legal decision, so persistence is less certain. The freshest verified October 1 quote was $32.095 at 09:32:36 ET, above the September 30 close, which shows early follow-through but does not determine the forecast direction for the remaining window. Risks include rapid momentum exhaustion, valuation sensitivity, and reversal if the conviction-list effect proves temporary. The 20-day dollar-volume figure is calculated from reported daily closes and volumes through September 30 and conservatively floored.
Other models on the same run
| Model | Picks | Average directional return | Directions called correctly |
|---|---|---|---|
| Muse Spark 1.1 | ACN, VICR, JBL, LQDA, UTHR | -1.90% | 20% |
| Perplexity | FICO, CTVA, LQDA, ACN, SNPS | -1.59% | 20% |
| Claude Sonnet 5.5 | UTHR, ROG, JBL, FORM, LQDA | +1.42% | 60% |
| Gemini 1.5 Pro | ROG, UTHR, JBL, FORM, ZETA | +2.92% | 100% |
| DeepSeek | HPE, UTHR, FORM, FICO, CEG | +0.21% | 40% |
Written up on ForecastNest Insights: Extreme Movers: GPT-5.6 Sol's picks for 2026-10-01.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.